Press Announcements > FDA alerts health care providers of adverse reactions associated with steroid injections from Main Street Family Pharmacy in Tennessee

Press Announcements > FDA alerts health care providers of adverse reactions associated with steroid injections from Main Street Family Pharmacy in Tennessee

FDA NEWS RELEASE

For Immediate Release: May 24, 2013
Media Inquiries: Christopher Kelly, 301-796-4676, christopher.kelly@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

FDA alerts health care providers of adverse reactions associated with steroid injections from Main Street Family Pharmacy in Tennessee

The U.S. Food and Drug Administration is working closely with the Centers for Disease Control and Prevention and Tennessee Board of Pharmacy to investigate reports of seven adverse events associated with steroid injections compounded by Main Street Family Pharmacy, LLC (Main Street) of Newbern, Tenn.

Out of an abundance of caution, the FDA recommends that health care providers not administer any products labeled as sterile from Main Street and quarantine them until further guidance is provided.

The reports of adverse events are all from patients who received preservative free methylprednisolone acetate (80 mg/mL) by injection. To date, the FDA has received seven reports. Clinical information about these patients is pending; at least one of these adverse events appears to involve fungus.

An investigation into the exact source of these adverse events is still ongoing, but these cases are associated with a potentially contaminated medication. As part of the ongoing investigation, the FDA will continue to work closely with the CDC and state authorities to thoroughly review the sterile practices at Main Street.

The FDA asks health care providers and consumers to report adverse events or quality problems experienced with the use of any Main Street products to the FDA’s MedWatch¹ Adverse Event Reporting program:

• Complete and submit the report online at www.fda.gov/medwatch/report.htm²
  
• Download and complete the form³, then submit it via fax at 1-800-FDA-0178